Six-month interim report May – October 2010/11

• Order bookings increased 12* percent to SEK 4,127 M (3,808).
• Net sales rose 15* percent to SEK 3,506 M (3,131).
• Operating profit increased to SEK 455 M (321).
• Net income rose to SEK 305 M (211).
• Earnings per share after dilution improved to SEK 3.24 (2.32).
• Cash flow from operating activities improved to SEK 204 M (150). Cash flow after
  investments was SEK -71 M (104), in which acquisitions were included with SEK -239 M. 
• In fiscal year 2010/11, net sales is expected to grow by more than 10 percent in local currency. Operating profit in SEK is expected to grow by more than 15 percent.

 Table included in attached PDF file

* Compared to last fiscal year at unchanged exchange rates.

President and CEO Tomas Puusepp comments 
I am very pleased with Elekta’s solid performance in the first six months of our fiscal year 2010/11. Demand remained strong for our clinical solutions and services. Order bookings increased by 12 percent in local currency. All product areas and regions showed growth, with particularly strong performance in Region Asia Pacific. In Region Europe, Middle East and Africa, development in the second quarter should be seen in the light of very strong order growth in the corresponding period of last year. Operating profit rose to SEK 455 M (321) mainly due to higher sales volumes.

Elekta’s success derives from providing increasingly sophisticated and comprehensive clinical solutions and services in the treatment of cancer and brain disease. By partnering with the foremost universities and hospitals worldwide Elekta paves the way for innovation and continuous improvement of patient care. Our world leading solutions in image-guided  radiation therapy, stereotactic radiosurgery and in oncology software, make it possible for oncologists and neurosurgeons to effectively treat tumors, blood vessel deformations and functional illnesses with maximum precision, while sparing healthy tissue.

Image guidance, motion management and workflow solutions are key areas of importance in the improvement of advanced cancer treatment. Our leading position in these areas is further strengthened by our latest addition to the product portfolio, Clarity™ soft tissue visualization, which can be integrated with any linear accelerator platform. Clarity received great attention at the 2010 meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in San Diego.

There is an increasing interest for stereotactic radiosurgery with an accelerating demand for Leksell Gamma Knife® Perfexion™. We expect advantages of stereotactic radiosurgery in the treatment of brain metastases to receive wider recognition worldwide in the coming years.

The need for cancer care is growing worldwide. Demand for Elekta’s clinical solutions is particularly strong in the emerging markets where Elekta is the market leader. Recently, China announced plans of doubling the number of linear accelerators over a period of five years. Russia is now on its second year of a national comprehensive program to expand cancer care throughout the country. We continue to make cancer care available for more people around the world through geographical expansion. Key success factors are our long term customer relations, our innovative capabilities and our commitment to the highest level of service and customer care.

Elekta’s financial outlook for the fiscal year 2010/11 remains unchanged of an increase in net sales by more than 10 percent in local currency, and operating profit increase in SEK of more than 15 percent.

Tomas Puusepp
President and CEO

For further information, please contact:
Håkan Bergström, CFO, Elekta AB (publ)
Tel: +46 8 587 25 547, e-mail: hakan.bergstrom@elekta.com

Stina Thorman, Vice President Corporate Communications, Elekta AB (publ)
Tel: +46 8 587 25 437, e-mail: stina.thorman@elekta.com